A method for treatment of neurodegenerative disease conditions stemming from multiple sclerosis, aging, autoimmune diseases and fibromyalgia. A compound effective to increase neuronal metabolism of histamine to a histamine H.sub.2 agonist is administered in an amount sufficient to stimulate production of cyclic AMP at a level which is sufficient to maintain myelin against undergoing self-degeneration. The compound is selected from the group consisting of histamine M-methyltransferase, monoamineoxidase-A, monoamineoxidase-A agonists and histamine H.sub.3 antagonists. The histamine M-methyltransferase may be administered to increase neuronal metabolism of histamine to tele-methylhistamine, whereas the monoamineoxidase-A or monoamineoxidase-A agonist may be administered so as to increase neuronal metabolism of telemethylhistamine to an H.sub.2 agonist. Separately or in conjunction with the others, the histamine H.sub.3 antagonist may be administered so as to inhibit metabolism of the telemethylhistamine to an H.sub.3 agonist, thereby increasing metabolism of the telemethylhistamine to an H.sub.2 agonist. The increased histamine H.sub.2 agonist levels reduce demyelination and the symptoms that are associated with these conditions.